Targeting protein kinases to reverse multidrug resistance in sarcoma.
暂无分享,去创建一个
Hua Chen | Zhenfeng Duan | Edwin Choy | Z. Duan | F. Hornicek | Francis J Hornicek | Hua Chen | E. Choy | Jacson K. Shen | Jacson Shen
[1] H. Colom,et al. Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours , 2014, British Journal of Cancer.
[2] Chaoliang He,et al. PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment. , 2014, Biomaterials.
[3] E. Appella,et al. Targeting Androgen Receptor/Src Complex Impairs the Aggressive Phenotype of Human Fibrosarcoma Cells , 2013, PloS one.
[4] Shanyong Zhang,et al. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells. , 2015, Oncology reports.
[5] Yan Luo,et al. Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway , 2014, Oncotarget.
[6] J. Blay,et al. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways. , 2014, Oncology reports.
[8] M. Bui,et al. MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells , 2011, Molecular Cancer Therapeutics.
[9] K. Horiuchi,et al. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells , 2015, Cancer science.
[10] S. Corey,et al. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma , 2008, Molecular Cancer Therapeutics.
[11] Adam Kiezun,et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma , 2014, Proceedings of the National Academy of Sciences.
[12] X. Bai,et al. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis. , 2014, Oncology reports.
[13] R. Versteeg,et al. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance , 2014, Investigational New Drugs.
[14] Elisa de Stanchina,et al. MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma , 2014, Molecular Cancer Therapeutics.
[15] C. Thiele,et al. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo , 2013, Oncotarget.
[16] M. Bui,et al. The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells , 2011, Molecular Cancer Therapeutics.
[17] C. Keller,et al. Dynamic and Nuclear Expression of PDGFRα and IGF-1R in Alveolar Rhabdomyosarcoma , 2013, Molecular Cancer Research.
[18] A. D. Dei Tos,et al. MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study , 2013, Molecular Cancer Therapeutics.
[19] M. Rivera,et al. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. , 2013, Cancer research.
[20] R. Gillies,et al. Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas , 2013, PloS one.
[21] D. Hicklin,et al. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. , 2006, Cancer research.
[22] X. Liang,et al. Expression of Aurora Kinase A and B in chondrosarcoma and its relationship with the prognosis , 2012, Diagnostic Pathology.
[23] Roy S Herbst,et al. Review of epidermal growth factor receptor biology. , 2004, International journal of radiation oncology, biology, physics.
[24] Chih-Hsin Tang,et al. HGF and c-Met Interaction Promotes Migration in Human Chondrosarcoma Cells , 2013, PloS one.
[25] Roger J. Davis,et al. The JIP Group of Mitogen-Activated Protein Kinase Scaffold Proteins , 1999, Molecular and Cellular Biology.
[26] S. Fulda,et al. PI3K Inhibition Enhances Doxorubicin-Induced Apoptosis in Sarcoma Cells , 2012, PloS one.
[27] R. Sciot,et al. Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features. , 2014, The international journal of biochemistry & cell biology.
[28] G. Superti-Furga,et al. An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B , 2011, Molecular Cancer Therapeutics.
[29] T. Hunter. A thousand and one protein kinases , 1987, Cell.
[30] D. Hughes,et al. Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy , 2015, Pediatric Drugs.
[31] M. Seckl,et al. A Novel Requirement for Janus Kinases as Mediators of Drug Resistance Induced by Fibroblast Growth Factor-2 in Human Cancer Cells , 2011, PloS one.
[32] S. Bhattacharya,et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. , 2002, Gene.
[33] A. Cleton-Jansen,et al. Targeting JNK-interacting protein 1 (JIP1) sensitises osteosarcoma to doxorubicin , 2012, Oncotarget.
[34] Wang Chuan-dong,et al. Chimaphilin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines through insulin-like growth factor-I receptor (IGF-IR) signaling. , 2015, Chemico-biological interactions.
[35] S. Fulda,et al. Synergistic induction of apoptosis by a polo‐like kinase 1 inhibitor and microtubule‐interfering drugs in Ewing sarcoma cells , 2016, International journal of cancer.
[36] M. Biffoni,et al. EGFR Inhibition Abrogates Leiomyosarcoma Cell Chemoresistance through Inactivation of Survival Pathways and Impairment of CSC Potential , 2012, PloS one.
[37] Xin Shi,et al. Focal adhesion kinase is involved in the migration of human osteosarcoma cells. , 2015, Oncology letters.
[38] Jingnan Shen,et al. Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients. , 2013, Biochemical and biophysical research communications.
[39] M. Schilham,et al. Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma , 2011, Clinical Cancer Research.
[40] C. Scapulatempo-Neto,et al. Gene Expression Profiling in Leiomyosarcomas and Undifferentiated Pleomorphic Sarcomas: SRC as a New Diagnostic Marker , 2014, PloS one.
[41] Yusuke Nakamura,et al. Activation of the non-canonical Dvl–Rac1–JNK pathway by Frizzled homologue 10 in human synovial sarcoma , 2009, Oncogene.
[42] Y. Matsuzaki,et al. Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro. , 2013, Oncology reports.
[43] R. Roskoski. A historical overview of protein kinases and their targeted small molecule inhibitors. , 2015, Pharmacological research.
[44] X. García del Muro,et al. Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas? , 2015, Expert review of anticancer therapy.
[45] Da-Yong Wang,et al. Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin , 2014, Tumor Biology.
[46] S. Millis,et al. Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets , 2015, Oncotarget.
[47] J. Ajani,et al. Cancer stem cells: the promise and the potential. , 2015, Seminars in oncology.
[48] P. Houghton,et al. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells , 2006, Molecular Cancer Therapeutics.
[49] Li-Huei Tsai,et al. Cyclin-dependent kinases: a family portrait , 2009, Nature Cell Biology.
[50] L. Qin,et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] W. Walsh,et al. IGF1R-Targeted Therapy and Its Enhancement of Doxorubicin Chemosensitivity in Human Osteosarcoma Cell Lines , 2011, Cancer investigation.
[52] R. Roskoski,et al. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. , 2015, Pharmacological research.
[53] C. Sander,et al. Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. , 2011, Cancer research.
[54] S. Fulda,et al. Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma. , 2015, Cancer letters.
[55] L. Nie,et al. MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[56] Huilin Yang,et al. Silencing of Aurora kinase A by RNA interference inhibits tumor growth in human osteosarcoma cells by inducing apoptosis and G2/M cell cycle arrest. , 2014, Oncology reports.
[57] R. Jove,et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. , 2007, Cancer research.
[58] Gongping Xu,et al. Inhibition of focal adhesion kinase induces apoptosis in human osteosarcoma SAOS-2 cells , 2014, Tumor Biology.
[59] D. Siemann,et al. Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model. , 2010, Anticancer research.
[60] K. Shimizu,et al. Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma , 2009, Journal of Cancer Research and Clinical Oncology.
[61] Z. Duan,et al. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway , 2010, BMC Cancer.
[62] N. Gray,et al. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells , 2014, BMC Cancer.
[63] Bin Wang,et al. Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo , 2010, Molecular and Cellular Biochemistry.
[64] J. Martín-Broto,et al. Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas , 2012, PloS one.
[65] Pierre Koch,et al. Inhibitors of c-Jun N-terminal kinases: an update. , 2015, Journal of medicinal chemistry.
[66] P. Meltzer,et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. , 2005, Cancer research.
[67] Robin L. Jones,et al. A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor {alpha} (PDGFR{alpha}) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS). , 2015 .
[68] Frederic Blanchard,et al. Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models , 2014, PloS one.
[69] W. Guo,et al. Arsenic trioxide inhibits Ewing’s sarcoma cell invasiveness by targeting p38MAPK and c-Jun N-terminal kinase , 2012, Anti-cancer drugs.
[70] Ricardo E. Perez,et al. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1 , 2014, Cancer biology & therapy.
[71] Mike Wilson,et al. IGF‐1 receptor contributes to the malignant phenotype in human and canine osteosarcoma , 2004, Journal of cellular biochemistry.
[72] J. Qin,et al. SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity , 2006, Cell.
[73] Haitao Ji,et al. Differential Regulation of c-Jun Protein Plays an Instrumental Role in Chemoresistance of Cancer Cells* , 2013, The Journal of Biological Chemistry.
[74] J. Doroshow,et al. Wee1 kinase as a target for cancer therapy , 2013, Cell cycle.
[75] A. Giordano,et al. SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation , 2015, Oncotarget.
[76] S. Ferrari,et al. Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. , 2011, European journal of cancer.
[77] H. Schreuder,et al. Expression and clinical relevance of MET and ALK in Ewing sarcomas , 2013, International journal of cancer.
[78] M. Clausen,et al. FDA-approved small-molecule kinase inhibitors. , 2015, Trends in pharmacological sciences.
[79] J. Blay,et al. Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas , 2013, Targeted Oncology.
[80] Francis Y. Lee,et al. MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions , 2012, Sarcoma.
[81] M. Bui,et al. Rapid Screening of Novel Agents for Combination Therapy in Sarcomas , 2013, Sarcoma.
[82] O. Larsson,et al. SRC signaling is crucial in the growth of synovial sarcoma cells. , 2013, Cancer research.
[83] S. Salas,et al. Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma , 2014, BMC Cancer.
[84] L. Qin,et al. Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma , 2015, Sarcoma.
[85] O. Stoeltzing,et al. The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®) , 2014, International journal of oncology.
[86] P. Meltzer,et al. Soft tissue sarcomas of adults: state of the translational science. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[87] S. Fulda,et al. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma. , 2015, Cancer letters.
[88] T. Dønnem,et al. Profiling of VEGFs and VEGFRs as Prognostic Factors in Soft Tissue Sarcoma: VEGFR-3 Is an Independent Predictor of Poor Prognosis , 2010, PloS one.
[89] S. Singer,et al. The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial , 2012, Clinical Cancer Research.
[90] Jingnan Shen,et al. miR-199a-3p negatively regulates the progression of osteosarcoma through targeting AXL. , 2014, American journal of cancer research.
[91] D. Heymann,et al. BYL719, a new α‐specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma , 2015, International journal of cancer.
[92] B. van de Water,et al. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells , 2013, British Journal of Cancer.
[93] Zhaoming Ye,et al. Prognostic value of IGF-1R expression in bone and soft tissue sarcomas: a meta-analysis , 2015, OncoTargets and therapy.
[94] D. Zuo,et al. Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal , 2015, Tumor Biology.
[95] B. Halmos,et al. AXL kinase as a novel target for cancer therapy , 2014, Oncotarget.
[96] E. Fleuren,et al. The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma , 2014, Oncotarget.
[97] J. Fargnoli,et al. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. , 2010, Cancer research.
[98] D. Sabatini,et al. mTOR Signaling in Growth Control and Disease , 2012, Cell.
[99] A. Spina,et al. Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53‐dependent pathway , 2013, Journal of cellular physiology.
[100] S. Fulda,et al. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs , 2015, Cell Death and Differentiation.
[101] O. Larsson,et al. Insulin‐like growth factor‐1 receptor acts as a growth regulator in synovial sarcoma , 2008, The Journal of pathology.
[102] Xianzhe Liu,et al. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo , 2011, Anti-cancer drugs.
[103] E. Raymond,et al. A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors , 2014, Investigational New Drugs.
[104] S. Arena,et al. Proteomics and phosphoproteomics provide insights into the mechanism of action of a novel pyrazolo[3,4-d]pyrimidine Src inhibitor in human osteosarcoma. , 2014, Molecular bioSystems.
[105] P. Schirmacher,et al. SRC inhibition represents a potential therapeutic strategy in liposarcoma , 2015, International journal of cancer.
[106] M. Malumbres,et al. From Plk1 to Plk5 , 2011, Cell cycle.
[107] A. Lazar,et al. Epidermal Growth Factor Receptor Blockade in Combination with Conventional Chemotherapy Inhibits Soft Tissue Sarcoma Cell Growth In vitro and In vivo , 2008, Clinical Cancer Research.
[108] Yang Li,et al. Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling. , 2012, Archives of biochemistry and biophysics.
[109] Y. Shin,et al. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma. , 2014, Histology and histopathology.
[110] C. Creighton,et al. Localized and metastatic myxoid/round cell liposarcoma , 2013, Cancer.
[111] R. Versteeg,et al. Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma , 2013, British Journal of Cancer.
[112] J. Mayerson,et al. Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions. , 2013, Anticancer research.
[113] Nam-Hui Yim,et al. A Novel Herbal Medicine, KIOM-C, Induces Autophagic and Apoptotic Cell Death Mediated by Activation of JNK and Reactive Oxygen Species in HT1080 Human Fibrosarcoma Cells , 2014, PloS one.
[114] P. Casali,et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. , 2015, The Lancet. Oncology.
[115] Agnieszka K. Witkiewicz,et al. The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.
[116] Lewis C Cantley,et al. The phosphoinositide 3-kinase pathway. , 2002, Science.